Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
No chromosome translocations, chimeric genes, or fusion proteins have been described in BIA-ALCL although the neoplastic cells in the disease have been described to have gene copy number variations involving gains in gene copies on the p arm of chromosome 19 and losses of gene copies in the p arms of chromosome 10 and 1. The neoplastic cells in BIA-ALCL show mutations of the STAT3 gene in 64% of cases and reports of mutations in JAK1, JAK3, DNMT3A, and TP53 genes. The development of BIA-ALCL, it has often been suggested, may be at least in part a T-cell-induced, inflammation-driven cancer response to the implant.
An important structural component of RNA that distinguishes it from DNA is the presence of a hydroxyl group at the 2' position of the ribose sugar. The presence of this functional group causes the helix to mostly take the A-form geometry, although in single strand dinucleotide contexts, RNA can rarely also adopt the B-form most commonly observed in DNA. The A-form geometry results in a very deep and narrow major groove and a shallow and wide minor groove. A second consequence of the presence of the 2'-hydroxyl group is that in conformationally flexible regions of an RNA molecule (that is, not involved in formation of a double helix), it can chemically attack the adjacent phosphodiester bond to cleave the backbone.
The FDA reviews commercially available test kits and their associated medical claims to ensure safety and efficacy before products are cleared or approved for use. The regulatory landscape for laboratory developed tests (LDTs) has been evolving significantly. On May 6, 2024, the FDA issued a final rule significantly modifying its approach to oversight of laboratory-developed tests, amending regulations to clarify that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act, including when manufactured by a laboratory. The final rule includes a policy under which FDA would phase out enforcement discretion for LDTs over a four-year period. The phaseout policy consists of five stages, starting May 6, 2024. DTC tests are specifically noted as having never been subject to enforcement discretion, meaning compliance with FDA requirements has always been expected for consumer-facing diagnostic tests. However, on April 17, 2025, a federal court blocked FDA's final rule on LDTs, creating uncertainty about the regulatory future. LDTs continue to be governed by CMS under CLIA oversight, but the long-term regulatory framework remains unsettled.
There are many diverse ways of monitoring enzyme levels through the use of enzyme inhibition. The general principle in many of these is the use the knowledge that many enzymes are driven by phosphate-releasing compounds such as adenosine triphosphate. Using radiolabelled 32P phosphate a fluorometric analysis can be used. Or unique polymers can be used to immobilize enzymes and act in an electrochemical biosensor. Overall, the benefits include a fast response time and little sample preparation. Some of the downsides include a lack of specificity in terms of being able to get readings of very small amounts of toxin and the rigidity of the assays in apply certain procedures to different toxins.
== Samarium-153 == Samarium-153 (153Sm) has a half-life of 46.285 hours, undergoing β− decay into stable 153Eu. As a component of samarium lexidronam, it is used in palliation of bone cancer. It is treated by the body in a similar manner to calcium, and it localizes selectively to bone.
Sources: en.wikipedia.org
This was confirmed by another meta-analysis involving 945 286 patients in 8 retrospective cohort studies, most in the US. In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007.
== Resignation and arrest == On 24 April 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office (KSC) located in The Hague filed a ten-count indictment for the court's consideration, charging Hashim Thaçi, Kadri Veseli and others for crimes against humanity and war crimes, including murder, enforced disappearance of persons, persecution, and torture. The indictment charged the suspects with approximately 100 murders of Kosovo Albanians, Serbs, Roma, and political opponents. According to the press release, the specialist prosecutor stated that it was necessary to make the issue public due to repeated efforts by Thaçi and Veseli to obstruct and undermine the Kosovo Specialist Chambers. Thaçi was then on a diplomatic visit to the United States, but returned to Kosovo on learning of the indictment. On 5 November 2020, Thaçi announced his resignation to reporters "to protect the integrity of the presidency of Kosovo". He was arrested the same day and transferred to The Hague. Thaçi was replaced by the speaker of the Assembly of Kosovo, Vjosa Osmani.
Anti-inflammatory: Calotropis extracts have been used traditionally to alleviate inflammation. The latex of the plant contains compounds that possess anti-inflammatory properties. Traditional uses of Calotropis include treating skin conditions such as eczema, psoriasis, and other inflammatory skin disorders. Its anti-inflammatory and wound-healing properties may contribute to these potential benefits. Antimicrobial: Certain parts of Calotropis, especially the latex, have shown antimicrobial activity against various bacterial and fungal pathogens. This property has been utilized in traditional medicine to treat skin infections and wounds. The antimicrobial activity of Calotropis plants has been attributed to the presence of various bioactive compounds such as alkaloids, flavonoids, and terpenoids. A study found that the latex of Calotropis procera has significant antimicrobial activity against various bacterial and fungal pathogens, including Staphylococcus aureus, Escherichia coli, and Candida albicans Wound Healing: The latex of Calotropis has been used topically to promote wound healing. It is believed to help in the formation of granulation tissue and facilitate the healing process. Analgesic (Pain Relief): Some traditional practices involve using Calotropis preparations to relieve pain and discomfort. Gastrointestinal Disorders: Some traditional medicinal practices use Calotropis to alleviate gastrointestinal issues such as constipation and dysentery. However, its laxative effects are strong and can lead to adverse effects.
== Awards == On 29 September 2014, President Goodluck Jonathan honoured Muhammad with the national award of the Officer of the Order of the Niger (OON) for his contributions to primary health care in Nigeria. In 2013, Muhammad won the Public Administrator of the Year Award (PAYA), organized annually by the Centre for Policy Development and Political Studies, Lagos, Nigeria. The centre said after announcing the winner that of the 10 nominees for the award, Muhammad scored 3,025 votes, representing over 50 percent of the total votes cast. He was praised for his efforts in "eradication of poliomyelitis; reduction in maternal and infant mortality; initiatives in addressing human resource challenges in the primary health care sub-sector; integration and decentralization of HIV/AIDs intervention in PHC services in over 1,500 PHC facilities." Muhammad also won the Kwame Nkrumah Leadership Award and the Africa Leadership Icon in 2014 at the 71st Conference of AASU, held at OATTU Conference Centre, in Accra, Ghana. The Kwame Nkrumah Leadership Award and Africa Leadership Icon 2014 are awarded by the All-Africa Students' Union (AASU).
Sources: en.wikipedia.org
=== EC 2.1.1: Methyltransferases === EC 2.1.1.1: nicotinamide N-methyltransferase EC 2.1.1.2: guanidinoacetate N-methyltransferase EC 2.1.1.3: thetin—homocysteine S-methyltransferase EC 2.1.1.4: acetylserotonin O-methyltransferase EC 2.1.1.5: betaine—homocysteine S-methyltransferase EC 2.1.1.6: catechol O-methyltransferase EC 2.1.1.7: nicotinate N-methyltransferase EC 2.1.1.8: histamine N-methyltransferase EC 2.1.1.9: thiol S-methyltransferase EC 2.1.1.10: homocysteine S-methyltransferase EC 2.1.1.11: magnesium protoporphyrin IX methyltransferase EC 2.1.1.12: methionine S-methyltransferase EC 2.1.1.13: methionine synthase EC 2.1.1.14: 5-methyltetrahydropteroyltriglutamate—homocysteine S-methyltransferase EC 2.1.1.15: fatty-acid O-methyltransferase EC 2.1.1.16: methylene-fatty-acyl-phospholipid synthase EC 2.1.1.17: phosphatidylethanolamine N-methyltransferase EC 2.1.1.18: polysaccharide O-methyltransferase EC 2.1.1.19: trimethylsulfonium—tetrahydrofolate N-methyltransferase EC 2.1.1.20: glycine N-methyltransferase EC 2.1.1.21: methylamine—glutamate N-methyltransferase EC 2.1.1.22: carnosine N-methyltransferase EC 2.1.1.23: now covered by EC 2.1.1.124, EC 2.1.1.125 and EC 2.1.1.126 EC 2.1.1.24: now covered by EC 2.1.1.77, EC 2.1.1.80 and EC 2.1.1.100 EC 2.1.1.25: phenol O-methyltransferase EC 2.1.1.26: iodophenol O-methyltransferase EC 2.1.1.27: tyramine N-methyltransferase EC 2.1.1.28: phenylethanolamine N-methyltransferase EC 2.1.1.29: Now covered by EC 2.1.1.202, EC 2.1.1.203 and EC .1.1.204 EC 2.1.1.30: tRNA (purine-2- or -6-)-methyltransferase: Reactions previously described are due to EC 2.1.1.32 EC 2.1.1.31: Now covered by EC 2.1.1.221 and EC 2.1.1.228 EC 2.1.1.32: Now covered by EC 2.1.1.213, EC 2.1.1.214, EC 2.1.1.215 and EC 2.1.1.216 EC 2.1.1.33: tRNA (guanine46-N7)-methyltransferase EC 2.1.1.34: tRNA (guanosine18-2′-O)-methyltransferase EC 2.1.1.35: tRNA (uracil54-C5)-methyltransferase EC 2.1.1.36: Now covered by EC 2.1.1.217, EC 2.1.1.218, EC 2.1.1.219, EC 2.1.1.220 EC 2.1.1.37: DNA (cytosine-5-)-methyltransferase EC 2.1.1.38: O-demethylpuromycin O-methyltransferase EC 2.1.1.39: inositol 3-methyltransferase EC 2.1.1.40: inositol 1-methyltransferase EC 2.1.1.41: sterol 24-C-methyltransferase EC 2.1.1.42: flavone 3′-O-methyltransferase EC 2.1.1.43: Now described by EC 2.1.1.354, EC 2.1.1.355, EC 2.1.1.356, EC 2.1.1.357, EC 2.1.1.358, EC 2.1.1.359, EC 2.1.1.360, EC 2.1.1.361 and EC 2.1.1.362 EC 2.1.1.44: L-histidine Nα-methyltransferase EC 2.1.1.45: thymidylate synthase EC 2.1.1.46: isoflavone 4′-O-methyltransferase EC 2.1.1.47: indolepyruvate C-methyltransferase EC 2.1.1.48: Now covered by EC 2.1.1.181, EC 2.1.1.182, EC 2.1.1.183 and EC 2.1.1.184 EC 2.1.1.49: amine N-methyltransferase EC 2.1.1.50: loganate O-methyltransferase EC 2.1.1.51: Now covered by EC 2.1.1.187 and EC 2.1.1.188 EC 2.1.1.52: Now covered by EC 2.1.1.171, EC 2.1.1.172, EC 2.1.1.173 and EC 2.1.1.174 EC 2.1.1.53: putrescine N-methyltransferase EC 2.1.1.54: deoxycytidylate C-methyltransferase EC 2.1.1.55: tRNA (adenine-N6-)-methyltransferase EC 2.1.1.56: mRNA (guanine-N7)-methyltransferase EC 2.1.1.57: methyltransferase cap1 EC 2.1.1.58: deleted, included in EC 2.1.1.57 EC 2.1.1.59: [cytochrome c]-lysine N-methyltransferase EC 2.1.1.60: calmodulin-lysine N-methyltransferase EC 2.1.1.61: tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase EC 2.1.1.62: mRNA (2′-O-methyladenosine-N6-)-methyltransferase EC 2.1.1.63: methylated-DNA—[protein]-cysteine S-methyltransferase EC 2.1.1.64: 3-demethylubiquinol 3-O-methyltransferase EC 2.1.1.65: licodione 2′-O-methyltransferase EC 2.1.1.66: Now covered by EC 2.1.1.230 EC 2.1.1.67: thiopurine S-methyltransferase EC 2.1.1.68: caffeate O-methyltransferase EC 2.1.1.69: 5-hydroxyfuranocoumarin 5-O-methyltransferase EC 2.1.1.70: 8-hydroxyfuranocoumarin 8-O-methyltransferase EC 2.1.1.71: phosphatidyl-N-methylethanolamine N-methyltransferase EC 2.1.1.72: site-specific DNA-methyltransferase (adenine-specific) EC 2.1.1.73: deleted: reaction is that of EC 2.1.1.37, DNA (cytosine-5-)-methyltransferase EC 2.1.1.74: methylenetetrahydrofolate—tRNA-(uracil54-C5)-methyltransferase [NAD(P)H-oxidizing] EC 2.1.1.75: apigenin 4′-O-methyltransferase EC 2.1.1.76: quercetin 3-O-methyltransferase EC 2.1.1.77: protein-L-isoaspartate(D-aspartate) O-methyltransferase EC 2.1.1.78: isoorientin 3′-O-methyltransferase EC 2.1.1.79: cyclopropane-fatty-acyl-phospholipid synthase EC 2.1.1.80: protein-glutamate O-methyltransferase EC 2.1.1.81: deleted, included in EC 2.1.1.49 EC 2.1.1.82: 3-methylquercetin 7-O-methyltransferase EC 2.1.1.83: 3,7-dimethylquercetin 4′-O-methyltransferase EC 2.1.1.84: methylquercetagetin 6-O-methyltransferase EC 2.1.1.85: protein-histidine N-methyltransferase EC 2.1.1.86: Now covered by EC 7.2.1.4 EC 2.1.1.87: pyridine N-methyltransferase EC 2.1.1.88: 8-hydroxyquercetin 8-O-methyltransferase EC 2.1.1.89: tetrahydrocolumbamine 2-O-methyltransferase EC 2.1.1.90: methanol—5-hydroxybenzimidazolylcobamide Co-methyltransferase EC 2.1.1.91: isobutyraldoxime O-methyltransferase EC 2.1.1.92: Now included with EC 2.1.1.69 EC 2.1.1.93: is identical to EC 2.1.1.70, 8-hydroxyfuranocoumarin 8-O-methyltransferase EC 2.1.1.94: tabersonine 16-O-methyltransferase EC 2.1.1.95: tocopherol C-methyltransferase EC 2.1.1.96: thioether S-methyltransferase EC 2.1.1.97: 3-hydroxyanthranilate 4-C-methyltransferase EC 2.1.1.98: diphthine synthase EC 2.1.1.99: 3-hydroxy-16-methoxy-2,3-dihydrotabersonine N-methyltransferase EC 2.1.1.100: protein-S-isoprenylcysteine O-methyltransferase EC 2.1.1.101: macrocin O-methyltransferase EC 2.1.1.102: demethylmacrocin O-methyltransferase EC 2.1.1.103: phosphoethanolamine N-methyltransferase EC 2.1.1.104: caffeoyl-CoA O-methyltransferase EC 2.1.1.105: N-benzoyl-4-hydroxyanthranilate 4-O-methyltransferase EC 2.1.1.106: tryptophan 2-C-methyltransferase EC 2.1.1.107: uroporphyrinogen-III C-methyltransferase EC 2.1.1.108: 6-hydroxymellein O-methyltransferase EC 2.1.1.109: demethylsterigmatocystin 6-O-methyltransferase EC 2.1.1.110: sterigmatocystin 8-O-methyltransferase EC 2.1.1.111: anthranilate N-methyltransferase EC 2.1.1.112: glucuronoxylan 4-O-methyltransferase EC 2.1.1.113: site-specific DNA-methyltransferase (cytosine-N4-specific) EC 2.1.1.114: polyprenyldihydroxybenzoate methyltransferase EC 2.1.1.115: (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline N-methyltransferase EC 2.1.1.116: 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase EC 2.1.1.117: (S)-scoulerine 9-O-methyltransferase EC 2.1.1.118: columbamine O-methyltransferase EC 2.1.1.119: 10-hydroxydihydrosanguinarine 10-O-methyltransferase EC 2.1.1.120: 12-hydroxydihydrochelirubine 12-O-methyltransferase EC 2.1.1.121: 6-O-methylnorlaudanosoline 5′-O-methyltransferase EC 2.1.1.122: (S)-tetrahydroprotoberberine N-methyltransferase EC 2.1.1.123: [cytochrome-c]-methionine S-methyltransferase EC 2.1.1.124: Now covered by EC 2.1.1.319, EC 2.1.1.320, EC 2.1.1.321 and EC 2.1.1.322 EC 2.1.1.125: Now covered by EC 2.1.1.319, EC 2.1.1.320 and EC 2.1.1.321 EC 2.1.1.126: Now covered by EC 2.1.1.319, EC 2.1.1.320 and EC 2.1.1.321 EC 2.1.1.127: [ribulose-bisphosphate carboxylase]-lysine N-methyltransferase EC 2.1.1.128: (RS)-norcoclaurine 6-O-methyltransferase EC 2.1.1.129: inositol 4-methyltransferase EC 2.1.1.130: precorrin-2 C20-methyltransferase EC 2.1.1.131: precorrin-2 C17-methyltransferase EC 2.1.1.132: precorrin-6B C5,15-methyltransferase (decarboxylating) EC 2.1.1.133: precorrin-4 C11-methyltransferase EC 2.1.1.134: now with EC 2.1.1.129 EC 2.1.1.135: now EC 1.16.1.8 EC 2.1.1.136: chlorophenol O-methyltransferase EC 2.1.1.137: arsenite methyltransferase EC 2.1.1.138: deleted: Reaction due to EC 2.1.1.137 EC 2.1.1.139: 3′-demethylstaurosporine O-methyltransferase EC 2.1.1.140: (S)-coclaurine-N-methyltransferase EC 2.1.1.141: jasmonate O-methyltransferase EC 2.1.1.142: cycloartenol 24-C-methyltransferase EC 2.1.1.143: 24-methylenesterol C-methyltransferase EC 2.1.1.144: trans-aconitate 2-methyltransferase EC 2.1.1.145: trans-aconitate 3-methyltransferase EC 2.1.1.146: (iso)eugenol O-methyltransferase EC 2.1.1.147: corydaline synthase EC 2.1.1.148: thymidylate synthase (FAD) EC 2.1.1.149: Now covered by EC 2.1.1.267, flavonoid 3′,5′-methyltransferase EC 2.1.1.150: isoflavone 7-O-methyltransferase EC 2.1.1.151: cobalt-factor II C20-methyltransferase EC 2.1.1.152: precorrin-6A synthase (deacetylating) EC 2.1.1.153: vitexin 2′′-O-rhamnoside 7-O-methyltransferase EC 2.1.1.154: isoliquiritigenin 2′-O-methyltransferase EC 2.1.1.155: kaempferol 4′-O-methyltransferase EC 2.1.1.156: glycine/sarcosine N-methyltransferase EC 2.1.1.157: sarcosine/dimethylglycine N-methyltransferase EC 2.1.1.158: 7-methylxanthosine synthase EC 2.1.1.159: theobromine synthase EC 2.1.1.160: caffeine synthase EC 2.1.1.161: dimethylglycine N-methyltransferase EC 2.1.1.162: glycine/sarcosine/dimethylglycine N-methyltransferase EC 2.1.1.163: demethylmenaquinone methyltransferase EC 2.1.1.164: demethylrebeccamycin-D-glucose O-methyltransferase EC 2.1.1.165: methyl halide transferase EC 2.1.1.166: 23S rRNA (uridine2552-2′-O)-methyltransferase EC 2.1.1.167: 27S pre-rRNA (guanosine2922-2′-O)-methyltransferase EC 2.1.1.168: 21S rRNA (uridine2791-2′-O)-methyltransferase EC 2.1.1.169: tricetin 3′,4′,5′-O-trimethyltransferase EC 2.1.1.170: 16S rRNA (guanine527-N7)-methyltransferase EC 2.1.1.171: 16S rRNA (guanine966-N2)-methyltransferase EC 2.1.1.172: 16S rRNA (guanine1207-N2))-methyltransferase EC 2.1.1.173: 23S rRNA (guanine2445-N2)-methyltransferase EC 2.1.1.174: 23S rRNA (guanine1835-N2)-methyltransferase EC 2.1.1.175: tricin synthase EC 2.1.1.176: 16S rRNA (cytosine967-C5)-methyltransferase EC 2.1.1.177: 23S rRNA (pseudouridine1915-N3)-methyltransferase EC 2.1.1.178: 16S rRNA (cytosine1407-C5)-methyltransferase EC 2.1.1.179: 16S rRNA (guanine1405-N7)-methyltransferase EC 2.1.1.180: 16S rRNA (adenine1408-N1)-methyltransferase EC 2.1.1.181: 23S rRNA (adenine1618-N6)-methyltransferase EC 2.1.1.182: 16S rRNA (adenine1518-N6/adenineadenine1519-N6)-dimethyltransferase EC 2.1.1.183: 18S rRNA (adenine1779-N6/adenine1780-N6)-dimethyltransferase EC 2.1.1.184: 23S rRNA (adenine2085-N6)-dimethyltransferase EC 2.1.1.185: 23S rRNA (guanosine2251-2′-O)-methyltransferase EC 2.1.1.186: 23S rRNA (cytidine2498-2′-O)-methyltransferase EC 2.1.1.187: 23S rRNA (guanine745-N1)-methyltransferase EC 2.1.1.188: 23S rRNA (guanine748-N1)-methyltransferase EC 2.1.1.189: 23S rRNA (uracil747-C5)-methyltransferase EC 2.1.1.190: 23S rRNA (uracil1939-C5)-methyltransferase EC 2.1.1.191: 23S rRNA (cytosine1962-C5)-methyltransferase EC 2.1.1.192: 23S rRNA (adenine2503-C2)-methyltransferase EC 2.1.1.193: 16S rRNA (uracil1498-N3)-methyltransferase EC 2.1.1.194: A mixture of EC 2.1.1.192 and EC 2.1.1.224 EC 2.1.1.195: cobalt-precorrin-5B (C1)-methyltransferase EC 2.1.1.196: cobalt-precorrin-7 (C15)-methyltransferase (decarboxylating) EC 2.1.1.197: malonyl-[acyl-carrier protein] O-methyltransferase EC 2.1.1.198: 16S rRNA (cytidine1402-2′-O)-methyltransferase EC 2.1.1.199: 16S rRNA (cytosine1402-N4)-methyltransferase EC 2.1.1.200: tRNA (cytidine32/uridine32-2′-O)-methyltransferase EC 2.1.1.201: 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase EC 2.1.1.202: multisite-specific tRNA:(cytosine-C5)-methyltransferase EC 2.1.1.203: tRNA (cytosine34-C5)-methyltransferase EC 2.1.1.204: tRNA (cytosine38-C5)-methyltransferase EC 2.1.1.205: tRNA (cytidine32/guanosine34-2′-O)-methyltransferase EC 2.1.1.206: tRNA (cytidine56-2′-O)-methyltransferase EC 2.1.1.207: tRNA (cytidine34-2′-O)-methyltransferase EC 2.1.1.208: 23S rRNA (uridine2479-2′-O)-methyltransferase EC 2.1.1.209: 23S rRNA (guanine2535-N1)-methyltransferase EC 2.1.1.210: demethylspheroidene O-methyltransferase EC 2.1.1.211: tRNASer(uridine44-2′-O)-methyltransferase EC 2.1.1.212: 2,7,4′-trihydroxyisoflavanone 4′-O-methyltransferase EC 2.1.1.213: tRNA (guanine110-N2)-dimethyltransferase EC 2.1.1.214: tRNA (guanine10-N2)-methyltransferase EC 2.1.1.215: tRNA (guanine26-N2/guanine27-N2)-dimethyltransferase EC 2.1.1.216: tRNA (guanine26-N2)-dimethyltransferase EC 2.1.1.217: tRNA (adenine22-N1)-methyltransferase EC 2.1.1.218: tRNA (adenine9-N1)-methyltransferase EC 2.1.1.219: tRNA (adenine57-N1/adenine58-N1)-methyltransferase EC 2.1.1.220: tRNA (adenine58-N1)-methyltransferase EC 2.1.1.221: tRNA (guanine9-N1)-methyltransferase EC 2.1.1.222: 2-polyprenyl-6-hydroxyphenyl methylase EC 2.1.1.223: tRNA1Val (adenine937-N6)-methyltransferase EC 2.1.1.224: 23S rRNA (adenine2503-C8)-methyltransferase EC 2.1.1.225: tRNA:m4X modification enzyme EC 2.1.1.226: 23S rRNA (cytidine1920-2′-O)-methyltransferase EC 2.1.1.227: 16S rRNA (cytidine1409-2′-O)-methyltransferase EC 2.1.1.228: tRNA (guanine37-N1)-methyltransferase EC 2.1.1.229: tRNA (carboxymethyluridine34-5-O)-methyltransferase EC 2.1.1.230: 23S rRNA (adenosine1067-2′-O)-methyltransferase EC 2.1.1.231: flavonoid 4′-O-methyltransferase EC 2.1.1.232: naringenin 7-O-methyltransferase EC 2.1.1.233: [phosphatase 2A protein]-leucine-carboxy methyltransferase EC 2.1.1.234: dTDP-3-amino-3,4,6-trideoxy-α-D-glucopyranose N,N-dimethyltransferase EC 2.1.1.235: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose N,N-dimethyltransferase EC 2.1.1.236: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose N,N-dimethyltransferase EC 2.1.1.237: mycinamicin III 3′′-O-methyltransferase EC 2.1.1.238: mycinamicin VI 2′′-O-methyltransferaseD EC 2.1.1.239: L-olivosyl-oleandolide 3-O-methyltransferase EC 2.1.1.240: trans-resveratrol di-O-methyltransferase EC 2.1.1.241: 2,4,7-trihydroxy-1,4-benzoxazin-3-one-glucoside 7-O-methyltransferase EC 2.1.1.242: 16S rRNA (guanine1516-N2)-methyltransferase EC 2.1.1.243: 2-ketoarginine methyltransferase EC 2.1.1.244: protein N-terminal methyltransferase EC 2.1.1.245: 5-methyltetrahydrosarcinapterin—corrinoid/iron-sulfur protein Co-methyltransferase EC 2.1.1.246: [methyl-Co(III) methanol-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.247: (methyl-Co(III) methylamine-specific corrinoid protein)—coenzyme M methyltransferase EC 2.1.1.248: methylamine—corrinoid protein Co-methyltransferase EC 2.1.1.249: dimethylamine—corrinoid protein Co-methyltransferase EC 2.1.1.250: trimethylamine—corrinoid protein Co-methyltransferase EC 2.1.1.251: methylated-thiol—coenzyme M methyltransferase EC 2.1.1.252: tetramethylammonium—corrinoid protein Co-methyltransferase EC 2.1.1.253: [methyl-Co(III) tetramethylammonium-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.254: erythromycin 3′′-O-methyltransferase EC 2.1.1.255: geranyl diphosphate 2-C-methyltransferase EC 2.1.1.256: tRNA (guanine6-N6-methyltransferase) EC 2.1.1.257: tRNA (pseudouridine54-N1)-methyltransferase EC 2.1.1.258: 5-methyltetrahydrofolate—corrinoid/iron-sulfur protein Co-methyltransferase EC 2.1.1.259: [fructose-bisphosphate aldolase]-lysine N-methyltransferase EC 2.1.1.260: rRNA small subunit pseudouridine methyltransferase Nep1 EC 2.1.1.261: 4-dimethylallyltryptophan N-methyltransferase EC 2.1.1.262: squalene methyltransferase EC 2.1.1.263: botryococcene C-methyltransferase EC 2.1.1.264: 23S rRNA (guanine2069-N7)-methyltransferase EC 2.1.1.265: tellurite methyltransferase EC 2.1.1.266: 23S rRNA (adenine2030-N6)-methyltransferase EC 2.1.1.267: flavonoid 3′,5′-methyltransferase EC 2.1.1.268: tRNAThr (cytosine32-N3)-methyltransferase EC 2.1.1.269: dimethylsulfoniopropionate demethylase EC 2.1.1.270: (+)-6a-hydroxymaackiain 3-O-methyltransferase EC 2.1.1.271: cobalt-precorrin-4 methyltransferase EC 2.1.1.272: cobalt-factor III methyltransferase EC 2.1.1.273: benzoate O-methyltransferase EC 2.1.1.274: salicylate 1-O-methyltransferase EC 2.1.1.275: gibberellin A9 O-methyltransferase EC 2.1.1.276: gibberellin A4 carboxyl methyltransferase EC 2.1.1.277: anthranilate O-methyltransferase EC 2.1.1.278: indole-3-acetate O-methyltransferase EC 2.1.1.279: trans-anol O-methyltransferase EC 2.1.1.280: selenocysteine Se-methyltransferase EC 2.1.1.281: phenylpyruvate C3-methyltransferase EC 2.1.1.282: tRNAPhe 7-[(3-amino-3-carboxypropyl)-4-demethylwyosine37-N4]-methyltransferase EC 2.1.1.283: emodin O-methyltransferase EC 2.1.1.284: 8-demethylnovobiocic acid C8-methyltransferase EC 2.1.1.285: demethyldecarbamoylnovobiocin O-methyltransferase EC 2.1.1.286: 25S rRNA (adenine2142-N1)-methyltransferase EC 2.1.1.287: 25S rRNA (adenine645-N1)-methyltransferase EC 2.1.1.288: aklanonic acid methyltransferase EC 2.1.1.289: cobalt-precorrin-7 (C5)-methyltransferase EC 2.1.1.290: tRNAPhe [7-(3-amino-3-carboxypropyl)wyosine37-O]-methyltransferase EC 2.1.1.291: (R,S)-reticuline 7-O-methyltransferase EC 2.1.1.292: carminomycin 4-O-methyltransferase EC 2.1.1.293: 6-hydroxytryprostatin B O-methyltransferase EC 2.1.1.294: 3-O-phospho-polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol 3-phospho-methyltransferase EC 2.1.1.295: 2-methyl-6-phytyl-1,4-hydroquinone methyltransferase EC 2.1.1.296: methyltransferase cap2 EC 2.1.1.297: peptide chain release factor N5-glutamine methyltransferase EC 2.1.1.298: ribosomal protein L3 N5-glutamine methyltransferase EC 2.1.1.299: protein N-terminal monomethyltransferase EC 2.1.1.300: pavine N-methyltransferase EC 2.1.1.301: cypemycin N-terminal methyltransferase EC 2.1.1.302: 3-hydroxy-5-methyl-1-naphthoate 3-O-methyltransferase EC 2.1.1.303: 2,7-dihydroxy-5-methyl-1-naphthoate 7-O-methyltransferase EC 2.1.1.304: L-tyrosine C3-methyltransferase EC 2.1.1.305: 8-demethyl-8-α-L-rhamnosyltetracenomycin-C 2′-O-methyltransferase EC 2.1.1.306: 8-demethyl-8-(2-methoxy-α-L-rhamnosyl)tetracenomycin-C 3′-O-methyltransferase EC 2.1.1.307: 8-demethyl-8-(2,3-dimethoxy-α-L-rhamnosyl)tetracenomycin-C 4′-O-methyltransferase EC 2.1.1.308: cytidylyl-2-hydroxyethylphosphonate methyltransferase EC 2.1.1.309: 18S rRNA (guanine1575-N7)-methyltransferase EC 2.1.1.310: 25S rRNA (cytosine2870-C5)-methyltransferase EC 2.1.1.311: 25S rRNA (cytosine2278-C5)-methyltransferase EC 2.1.1.312: 25S rRNA (uracil2843-N3)-methyltransferase EC 2.1.1.313: 25S rRNA (uracil2634-N3)-methyltransferase EC 2.1.1.314: diphthine methyl ester synthase EC 2.1.1.315: 27-O-demethylrifamycin SV methyltransferase EC 2.1.1.316: mitomycin 6-O-methyltransferase EC 2.1.1.317: sphingolipid C9-methyltransferase EC 2.1.1.318: [trehalose-6-phosphate synthase]-L-cysteine S-methyltransferase EC 2.1.1.319: type I protein arginine methyltransferase EC 2.1.1.320: type II protein arginine methyltransferase EC 2.1.1.321: type III protein arginine methyltransferase EC 2.1.1.322: type IV protein arginine methyltransferase EC 2.1.1.323: (–)-pluviatolide 4-O-methyltransferase EC 2.1.1.324: dTDP-4-amino-2,3,4,6-tetradeoxy-D-glucose N,N-dimethyltransferase EC 2.1.1.325: juvenile hormone-III synthase EC 2.1.1.326: N-acetyldemethylphosphinothricin P-methyltransferase EC 2.1.1.327: phenazine-1-carboxylate N-methyltransferase EC 2.1.1.328: N-demethylindolmycin N-methyltransferase EC 2.1.1.329: demethylphylloquinol methyltransferase EC 2.1.1.330: 5′-demethylyatein 5′-O-methyltransferase EC 2.1.1.331: bacteriochlorophyllide d C-121-methyltransferase EC 2.1.1.332: bacteriochlorophyllide d C-82-methyltransferase EC 2.1.1.333: bacteriochlorophyllide d C-20 methyltransferase EC 2.1.1.334: methanethiol S-methyltransferase EC 2.1.1.335: 4-amino-anhydrotetracycline N4-methyltransferase EC 2.1.1.336: norbelladine O-methyltransferase EC 2.1.1.337: reticuline N-methyltransferase EC 2.1.1.338: desmethylxanthohumol 6′-O-methyltransferase EC 2.1.1.339: xanthohumol 4-O-methyltransferase EC 2.1.1.340: 3-aminomethylindole N'-methyltransferase EC 2.1.1.341: vanillate/3-O-methylgallate O-demethylase EC 2.1.1.342: anaerobilin synthase EC 2.1.1.343: 8-amino-8-demethylriboflavin N,N-dimethyltransferase EC 2.1.1.344: ornithine lipid N-methyltransferase EC 2.1.1.345: psilocybin synthase EC 2.1.1.346: U6 snRNA m6A methyltransferase EC 2.1.1.347: (+)-O-methylkolavelool synthase EC 2.1.1.348: mRNA m6A methyltransferase EC 2.1.1.349: toxoflavin synthase EC 2.1.1.350: menaquinone C8-methyltransferase EC 2.1.1.351: nocamycin O-methyltransferase EC 2.1.1.352: 3-O-acetyl-4′-O-demethylpapaveroxine 4′-O-methyltransferase EC 2.1.1.353: demethylluteothin O-methyltransferase EC 2.1.1.354: [histone H3]-lysine4 N-trimethyltransferase EC 2.1.1.355: [histone H3]-lysine9 N-trimethyltransferase EC 2.1.1.356: [histone H3]-lysine27 N-trimethyltransferase EC 2.1.1.357: [histone H3]-lysine36 N-dimethyltransferase EC 2.1.1.358: [histone H3]-dimethyl-L-lysine36 N-methyltransferase. Now known to have the activity of EC 2.1.1.359, [histone H3]-lysine36 N-trimethyltransferase. EC 2.1.1.359: [histone H3]-lysine36 N-trimethyltransferase EC 2.1.1.360: [histone H3]-lysine79 N-trimethyltransferase EC 2.1.1.361: [histone H4]-lysine20 N-methyltransferase EC 2.1.1.362: [histone H4]-N-methyl-L-lysine20 N-methyltransferase EC 2.1.1.363: pre-sodorifen synthase EC 2.1.1.364: [histone H3]-lysine4 N-methyltransferase EC 2.1.1.365: MMP 1-O-methyltransferase EC 2.1.1.366: [histone H3]-N6,N6-dimethyl-lysine9 N-methyltransferase EC 2.1.1.367: [histone H3]-lysine9 N-methyltransferase EC 2.1.1.368: [histone H3]-lysine9 N-dimethyltransferase EC 2.1.1.369: [histone H3]-lysine27 N-methyltransferase EC 2.1.1.370: [histone H3]-lysine4 N-dimethyltransferase EC 2.1.1.371: [histone H3]-lysine27 N-dimethyltransferase EC 2.1.1.372: [histone H4]-lysine20 N-trimethyltransferase EC 2.1.1.373: 2-hydroxy-4-(methylsulfanyl)butanoate S-methyltransferase EC 2.1.1.374: 2-heptyl-1-hydroxyquinolin-4(1H)-one methyltransferase EC 2.1.1.375: NNS virus cap methyltransferase EC 2.1.1.376: glycine betaine—corrinoid protein Co-methyltransferase EC 2.1.1.377: [methyl-Co(III) glycine betaine-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.378: [methyl-Co(III) glycine betaine-specific corrinoid protein]—tetrahydrofolate methyltransferase EC 2.1.1.379: [methyl coenzyme M reductase]-L-arginine C-5-methyltransferase
== Restraint generation == In order to make structure calculations, a number of experimentally determined restraints have to be generated. These fall into different categories; the most widely used are distance restraints and angle restraints.
Dinosterol has been used as a biomarker for dinoflagellates whose sedimentary concentration has been correlated with changes in marine production rates. In a study by Schubert et al., it was shown that dinosterol has a concordant concentration maximum that coincides with organic carbon maxima over the past 200,000 years in a sediment core from the northeastern Arabian Sea. In this study, dinosterol was used to trace changes in ocean production in the Arabian Sea. Due to similar distributions of dinosterol and brassicasterol, a biomarker indicative of diatom abundances, it was concluded that the relative contributions of the dominant members of the phytoplankton community to production were uniform on timescales greater than 3,000–4,000 years over the past 200,000 years, despite overall paleoproduction having changed dramatically. Cross-spectral analysis of overall marine production (Corg) and biomarkers, dinosterol and brassicasterol, show very high spectral coherencies, supporting the correlation between Corg and dinosterol.
== Structure == The asymmetric unit of cyanophycinase consists of three identical chains, each containing 291 residues. The structure of cyanophycinase was determined from the freshwater cyanobacterium Synechocystis sp. PCC 6803 at 1.5-A resolution, which showed that the structure is dimeric.
=== 2.1a === VESA announced version 2.1a of the DisplayPort standard on 8 January 2024. This version replaces the DP40 cable certification with the new DP54 certification, which tests DisplayPort cables for proper operation at the UHBR13.5 (54 Gbit/s) speed introduced in version 2.0.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.